Tele No.011-23236965
Fax.No.011-23236973

F. No. ND/MA/22/000139
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

06 JAN 2023

To
M/s Zenara Pharma Private Limited,
Plot No 83/B,84 & 87-96, Phase III,
IDA Cherlapally, Hyderabad (India) -500051.

Subject: Application for permission to conduct "A prospective, randomised, double-blind, multicenter comparative study to Evaluate the Efficacy, Safety and Pharmacokinetics of Cannabidiol oral solution versus matching placebo for treatment of mild to moderate anxiety disorders". –Regarding.

CT NOC No.: CT/ND/60/2022

Sir,

With reference to your application no. **ND/CT21/FF/2022/34034 dated 21.09.2022**; please find enclosed herewith the permission in **Form CT-06, No. CT/ND/60/2022** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

(Dr. V. G. Somani)
Central Licensing Authority

Conditions of permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby **M/s Zenara Pharma Private Limited, Plot No 83/B,84 & 87-96, Phase III, IDA Cherlapally, Hyderabad (India) -500051 Telephone No.: 91-40-27260848 FAX: 91-40-27260849, E-Mail: BHANUPRAKASH@ZENARA.CO.IN** to conduct clinical trial of the investigational new drug as per Protocol Number: **CP-CBD001-22,** Protocol Version: **4.0**, Protocol Date: **01-NOV-2022** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug or investigational new drug:		**Cannabidiol Oral Solution 150mg/ml**
Therapeutic class:		**Anxiolytic**
Dosage form:		**Oral Solutions**
Composition:		**Each mL contains Cannabidiol..... 150 mg**
Indications:		**Indicated for the management of mild to moderate anxiety disorders in conjunction with cognitive behavioural therapy**
Details of clinical trial sites-		
Sr. No.	**Name of Principal Investigator & Trial Sites**	**Ethics Committee Name/ Registration Number**
01	Dr. Prasad Rao G, Asha Hospital, Road No 14, Banjara Hills, Hyderabad - 500034,	Ethics Committee Asha Hospital, 8-2-316/12/A, Road No.14, Banjara Hills Hyderabad, Telangana - 500034 India. EC Registration No: ECR/177/Inst/AP/2013/ RR-20
02	Dr. Gediya Alpesh Jayantibhai, GCS Medical College, Hospital & Research Centre, Opp. DRM Office, Nr. Chamunda Bridge, Naroda Road, Ahmedabad-380025, Gujarat, India.	IEC, GCS Medical College, Hosp and Research Centre, GCS Medical College, Hospital and Research Centre Opp. DRM Office Naroda Road Ahmedabad Ahmedabad Gujarat - 380025 India. EC Registration No: ECR/339/Inst/GJ/2013/RR-19
03	Dr. P. Lokeshwara Reddy, Guntur General Hospital, Opposite Railway Station, Sambasiva Pet, Railpet, Guntur - 522001,	ETHICS COMMITTEE GMC and GGH Guntur Medical College Kannavari Thota, Main Road Guntur Guntur, Andhra Pradesh- 522004 India. EC Registration No: ECR/467/Inst/AP/2013/RR-19
04	Dr. A. Ugandhara Reddy Vijaya Super Speciality	Vijaya Ethics Committee, Vijaya Super Speciality Hospital Raghava Cini Complex Road Poghatota

	Hospital, Door No. 16 II/41-A, Raghava Cine Complex Road, Poga Thota, Nellore-524001	Nellore Nellore Andhra Pradesh - 524001 India EC Registration No: ECR/453/Inst/AP/2013/RR-19
05	Dr. Nishanth Vemana, Excel Hospital, 1-5-56/29, Near IG Statue, Beside Bharat Petrollium, Old alwal Secondarabad, Telangana-500010	Excel Hospital Institutional Ethics Committee Excel Hospital - A Unit Of Bhargava Sai Healthcare, 1-5-56/29, Near IG Statue,Old Alwal Medchal, Secunderabad Medchal Medchal–Malkajgiri Telangana- 500010 India EC Registration No: ECR/1670/Inst/TG/2022
06	Dr. Ashish Mukhopadhyay, NRS Medical College and hospital, 138, Acharya Jagadish Chandra Bose Rd, Sealdah, Raja Bazar, Kolkata, West Bengal 700014	Ethics Committee, NRS Medical College And Hospital NRS Medical College 138, A.J.C Bose Road Kolkata Kolkata West Bengal - 700014 India. EC Registration No: ECR/609/Inst/WB/2014/RR-20
07	Dr. Sandeep Grover, Postgraduate Institute of Medical Education & Research (PGIMER), Sector-12, Uttaranchal, Chandigarh 160012.	Institutional Ethics Committee, Post Graduate Institute of Medical Education and Research, Room No. 6006, IEC Office, 6th Floor, P N Chuttani Block Chandigarh-160012 India. EC Registration No: ECR/25/Inst/CH/2013/RR-20
08	Dr. Vikhram R, Ahana Hospitals LLP, No.7, Subburaman Street, Gandhi Nagar, Madurai – 625020, Tamilnadu, India.	Ethics Committee, Radianz healthcare and research Ahana Hospitals, No.11.Subburam Street Gandhi Nagar Madurai, Madurai Tamil Nadu - 625020 India EC Registration No: ECR/546/Inst/TN/2014/ RR-20
09	Dr.Medikonda Meena Kumari Latha Super Specialities Hospital, D.N: 29-14-58, Prakasam Road, Suryaraopet, Vijayawada-2, Andhra Pradesh, India.	Latha Super specialities Hospital Ethics Committee Latha Super Specialities Hospital Prakasam Road, Suryaraopet Vijayawada Krishna Andhra Pradesh - 520002 India. EC Registration No: ECR/1478/Inst/AP/2020

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

(Dr. V. G. Somani)
Central Licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi
Date: .....

06 JAN 2023

CT NOC NO. CT/ND/60/2022